Detailed Narrative
Q2 & H1 FY24 Financial Performance Overview
Gujarat Themis Biosyn Limited reported a challenging Q2 FY24, with revenues decreasing by 16.86% year-on-year to Rs.39.65 crores. EBITDA saw a sharper decline of 31% to Rs.16.82 crores, leading to an EBITDA margin of 42.42%, down 875 basis points from the previous year. Net profit for the quarter fell by 32.93% to Rs.12.54 crores, with an EPS of Rs.8.63. For the first half of FY24, revenues were Rs.89.24 crores (down 3.66% YoY), EBITDA was Rs.40.33 crores (margin 45.19%), and PAT was Rs.30.27 crores (down 15.91% YoY), with an EPS of Rs.20.83.
Strategic CAPEX and R&D Initiatives
The company's CAPEX plan is progressing as scheduled, with Rs.60 crores currently under capital work-in-progress. Both the R&D facility and the API block are on track to be commissioned by December 2023. This new infrastructure is expected to expedite product development and broaden the fermentation-based product portfolio. Additionally, construction for additional fermentation capacity is underway and is targeted for completion by 2025, aiming to meet global regulatory norms and target export markets.
Focus on Rifapentine and Forward Integration
Gujarat Themis Biosyn is strategically focusing on Rifapentine, an API for tuberculosis treatment, which is gaining preference from WHO. The company has built an initial capacity of 7 to 8 MT per month for Rifapentine production. Management highlighted the 'massive upside' and 'extremely interesting' pricing for Rifapentine, with import prices ranging from $450 to $500 per Kg, significantly higher than Rifampicin's $160-$170 per Kg. This forward integration is expected to yield better margins than current products.
Capacity Utilization and Inventory Management
In Q2 FY24, the company maintained optimal production levels. Management clarified that while Q1 FY24 benefited from sales of built-up inventory from previous quarters, Q2 saw inventory normalization, leading to lower reported turnover. Currently, the company is selling whatever it produces, indicating strong demand and good capacity utilization. The annualized revenue based on Q2's Rs.40 crores run rate is approximately Rs.160 crores, with new API block revenues expected to contribute from the next financial year.
Margin Pressures and Cost Factors
EBITDA margins faced pressure in Q2 FY24 due to several factors. These included higher investments in skilled workforce, increased R&D costs, and some one-time📎 expenses. Management noted that R&D expenses are expected to fluctuate quarter-on-quarter as development activities intensify. Additionally, utility costs, primarily power and energy, are a significant expense, and rising power tariffs directly impact the company's cost structure, prompting exploration of alternatives.
Customer Relationships and Market Dynamics
The company maintains strong relationships with its two key customers, Lupin and Optimus, and aims to fulfill their requirements while pursuing its own forward integration. Management stated that the new API block facilities are designed to be compliant with global regulatory norms, enabling sales in diverse international markets. They also confirmed applying for incentives from the Gujarat Government Biotech Promotion Board for the new CAPEX, but not for the central PLI scheme.